Phase 3 EV-302 trial demonstrates PADCEV plus KEYTRUDA reduces mortality risk by 49% compared to chemotherapy in advanced urothelial cancer patients, with median overall survival of 33.8 months versus 15.9 months.
Immunotherapy and antibody-drug conjugates (ADCs) are transforming urothelial carcinoma treatment, prompting investigation into bladder-sparing approaches.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.